查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球臨床微生物學市場：市場規模、佔有率、趨勢：按應用、按疾病、按產品、按最終用戶、按地區 - 預測至 2029 年
市場調查報告書
商品編碼
1499310

全球臨床微生物學市場：市場規模、佔有率、趨勢：按應用、按疾病、按產品、按最終用戶、按地區 - 預測至 2029 年

Clinical Microbiology Market Size, Share & Trends by Application, Disease, Product, End User, and Region - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 339 Pages | 訂單完成後即時交付

價格
簡介目錄

臨床微生物學市場規模預計將從 2024 年的 50 億美元增加到 2029 年的 69 億美元，預測期內複合年成長率為 6.5%。

由於疾病診斷領域的最新技術進步，例如快速分子測試和實驗室自動化，可以更快、更準確地檢測傳染源，臨床微生物學市場正在經歷顯著成長。此外，人口成長、都市化和國際旅行導致全球感染疾病率上升，推動了對先進微生物檢測解決方案的需求。然而，諸如微生物檢測方法有限的報銷政策、對熟練人員的需求等操作障礙以及複雜的法律規範框架等挑戰對市場擴張構成了障礙，尤其是在資源有限的環境中。應對這些挑戰對於提高世界各地微生物檢測服務的可近性和可負擔性至關重要。

調查範圍
調查年份 2021-2029
基準年 2023年
預測期 2024-2029
考慮單位 金額（十億美元）
部分 按應用程式、疾病、產品、最終用戶、地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東非洲

預計設備領域將在整個預測期內主導臨床微生物學檢測產業。該細分市場的巨大市場佔有率歸因於多種因素。首先，研究人員和學術界已大量採用傳統實驗室設備，並且以基因組研究為重點的產學界合作顯著增加。其次，分子技術和蛋白質組學的進步，包括微流體和 PCR 的整合以及奈米技術在 qPCR 技術中的應用等創新，正在推動該領域的成長。最後，臨床實驗室測試自動化的趨勢正在促進臨床微生物學產業設備領域的擴展和崛起。

製藥領域佔據了臨床微生物檢測行業最大的應用領域，預計在整個預測期內將保持其主導地位。這一巨大佔有率主要歸因於藥品生產和原料採購過程中微生物污染評估的完善且廣泛接受的法規。 WHO、FDA、MHRA（英國）、歐洲藥品管理局（EU）、TGA（澳洲）和ANVISA（巴西）等監管機構要求輔料確保無菌藥物生產和成品藥物的微生物負荷測試，並制定了嚴格的指導方針。此外，藥品生產過程根據世界各地的各種藥典進行嚴格監控。全球藥品產量的增加也對該應用領域的成長做出了重大貢獻。

該報告研究了全球臨床微生物學市場，包括有關應用、疾病、產品、最終用戶、地區、區域趨勢以及參與市場的公司概況的資訊。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 價格分析
  • 專利分析
  • 價值鏈分析
  • 供應鏈分析
  • 貿易分析
  • 生態系分析
  • 波特五力分析
  • 主要相關人員和採購標準
  • 監管狀況
  • 技術分析
  • 2024-2025年重大會議和活動
  • 影響客戶業務的趨勢/干擾
  • 投資金籌措場景
  • 未滿足的需求

第6章臨床微生物學市場（按應用）

  • 介紹
  • 藥品
  • 臨床
  • 食品檢驗
  • 能源
  • 化學及材料製造
  • 環境

第7章臨床微生物學市場（按疾病）

  • 介紹
  • 呼吸系統疾病
  • 血流感染疾病
  • 胃腸道疾病
  • 性行為感染傳染病
  • 尿道感染
  • 牙周疾病
  • 其他

第8章臨床微生物學市場（按產品）

  • 介紹
  • 裝置
  • 試劑
  • 中等，SERA

第9章臨床微生物學市場（按最終用戶）

  • 介紹
  • 醫院和診斷中心
  • 測試合約組織
  • 學術研究所

第10章臨床微生物學市場（按地區）

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第11章競爭格局

  • 介紹
  • 主要參與企業的策略/秘密
  • 收益分析
  • 市場佔有率分析
  • 企業評估矩陣：主要參與企業，2023
  • 企業評估矩陣：Start-Ups/小型企業，2023 年
  • 評價及財務指標
  • 品牌/產品比較
  • 競爭場景

第12章 公司簡介

  • 主要參與企業
    • BIOMERIEUX
    • DANAHER CORPORATION
    • BECTON, DICKINSON AND COMPANY
    • ABBOTT
    • F. HOFFMANN-LA ROCHE LTD.
    • THERMO FISHER SCIENTIFIC INC.
    • AGILENT TECHNOLOGIES, INC.
    • BRUKER
    • HOLOGIC, INC.
    • MERCK KGAA
    • BIO-RAD LABORATORIES, INC.
    • QIAGEN
    • SHIMADZU CORPORATION
    • NEOGEN CORPORATION
    • SIEMENS HEALTHINEERS AG
    • HARDY DIAGNOSTICS
    • EMSL ANALYTICAL, INC.
    • LIOFILCHEM SRL
    • TCS BIOSCIENCES
    • COLE-PARMER INSTRUMENT COMPANY, LLC
  • 其他公司
    • MEMMERT GMBH+CO.KG
    • VACUTEST KIMA SRL
    • RAPID MICRO BIOSYSTEMS, INC.
    • BIOTECHNOLOGY SOLUTIONS TX, LLC
    • ARROW DIAGNOSTICS

第13章附錄

簡介目錄
Product Code: MD 3092

The Clinical microbiology market is projected to reach USD 6.9 billion by 2029 from USD 5.0 billion in 2024 with a CAGR of 6.5% during the forecast period. The clinical microbiology market is experiencing significant growth driven by recent technological advancements in disease diagnostics, such as rapid molecular testing and laboratory automation, aiding faster and more precise detection of infectious agents. Additionally, the rising global incidence of infectious diseases due to population growth, urbanization, and international travel is driving demand for advanced microbiology testing solutions. However, challenges including limited reimbursement policies for microbiology testing procedures and operational barriers like the need for skilled personnel and complex regulatory frameworks pose obstacles to market expansion, particularly in resource-constrained settings. Addressing these challenges will be crucial to improving accessibility and affordability of microbiology testing services worldwide.

Scope of the Report
Years Considered for the Study2021-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsType, Application, Disease and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America and Middle East Africa

"The Instruments segment accounted for a substantial share of the clinical microbiology market, by type in 2023."

The instruments segment is projected to dominate the clinical microbiology industry throughout the forecast period. This segment's substantial market share can be attributed to several factors. Firstly, there is significant adoption of conventional laboratory instruments by researchers and academia, with a notable increase in industry-academia collaborations focused on genomic research. Secondly, advancements in molecular techniques and proteomics, including innovations such as integrating microfluidics with PCR and applying nanotechnology to qPCR techniques, are driving the segment's growth. Lastly, the ongoing trend of laboratory automation among clinical laboratories is contributing to the expansion and prominence of the instruments segment within the clinical microbiology industry.

" By Application Pharmaceutical Application segment accounted for the largest share in the healthcare clinical microbiology market."

The pharmaceuticals segment represents the largest application area within the clinical microbiology industry and is expected to maintain its dominance throughout the forecast period. This significant share can be primarily attributed to the presence of well-established and widely accepted regulations governing microbial contamination evaluation during pharmaceutical manufacturing and raw material procurement. Regulatory bodies such as the WHO, FDA, MHRA (UK), European Medicines Agency (EU), TGA (Australia), and ANVISA (Brazil) have defined stringent guidelines for assessing microbial contamination in excipients and active pharmaceutical ingredients (APIs) to ensure sterile drug manufacturing and microbial load testing of finished pharmaceutical products. Moreover, pharmaceutical manufacturing processes are rigorously monitored and controlled according to various pharmacopeias on a global scale. The increasing production volume of pharmaceutical drugs worldwide also contributes significantly to the growth of this application segment.

"North America to witness the substantial growth rate during the forecast period."

North America, which includes the United States and Canada, holds a leading position in the clinical microbiology market. This region is characterized by its maturity, marked by widespread use of clinical microbiology technologies among key end-users such as hospitals, research laboratories, diagnostic centers, and commercial service providers. Additionally, North America benefits from well-established distribution channels for manufacturers and suppliers of clinical microbiology products. The region's growth is propelled by factors including easy accessibility to and high adoption of advanced diagnostic technologies, supported by substantial per capita healthcare expenditure by the US and Canadian governments annually, along with favorable government regulations that foster industry development.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
  • By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
  • By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, ROW-10%

Key Players in the Clinical Microbiology Market

The prominent players in the global healthcare clinical microbiology market include BioMerieux (France), Danaher Corporation (US), Becton, Dickinson, and Company (BD) (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Bruker (US), Hologic, Inc. (US), Merck KGaA(Germany), Bio-Rad Laboratories, Inc.(US), QIAGEN(Netherlands), Shimadzu Corporation(Japan), Neogen Corporation (US), Siemens Healthineers AG (Germany). With Emerging players including, Hardy Diagnostics (US), EMSL Analytical, Inc. (US), Lofilchem S.R.L (Italy), TCS Biosciences (UK), Cole-Parmer Instrument Company, LLC (US), Memmert GmbH + Co.KG (Germany), Vacutest Kima S.r.l (Germany), Rapid Micro Biosystems, Inc. (US), Biotechnology Solutions TX, LLC (US), and Arrow Diagnostics Srl (Italy).

Research Coverage:

The report analyzes the Clinical microbiology market and aims to estimate the market size and future growth potential of various market segments, based on type, application, disease, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Analysis of Market Dynamics (Rising incidence of infectious diseases, technological advancements in disease diagnostics,), restraints (limited reimbursement policies for clinical microbiology testing products), opportunities (Improving healthcare infrastructure among emerging economies), and challenges (operational barriers related to use of diagnostics tests)
  • Products/Innovations: Detailed insights on upcoming technologies, research & development activities, and new service launches in the Clinical microbiology market.
  • Market Development: Comprehensive information on the lucrative emerging markets, component, demographics , end-user, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the clinical microbiology market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the clinical microbiology market like BioMerieux (France), Danaher Corporation (US), Becton, Dickinson, and Company (BD) (US), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Bruker (US), Hologic, Inc. (US) among others.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
    • TABLE 1 CLINICAL MICROBIOLOGY MARKET: INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 SEGMENTS COVERED
    • FIGURE 1 CLINICAL MICROBIOLOGY MARKET: SEGMENTS COVERED
    • 1.3.2 REGIONS COVERED
    • FIGURE 2 CLINICAL MICROBIOLOGY MARKET: REGIONS COVERED
    • 1.3.3 YEARS CONSIDERED
    • FIGURE 3 CLINICAL MICROBIOLOGY MARKET: YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
    • 1.3.5 UNITS CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
    • 1.5.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 4 CLINICAL MICROBIOLOGY MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 List of key secondary sources
      • 2.1.1.2 Key data from secondary sources
      • 2.1.1.3 Objectives of secondary research
    • 2.1.2 PRIMARY DATA
    • FIGURE 5 KEY PRIMARY SOURCES FROM DEMAND AND SUPPLY SIDES
      • 2.1.2.1 Objectives of primary research
      • 2.1.2.2 Key data from primary sources
    • TABLE 2 KEY DATA OBTAINED FROM PRIMARY SOURCES
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primaries
    • FIGURE 6 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Company revenue estimation approach
    • FIGURE 8 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.2.1.2 Company presentations and primary interviews
      • 2.2.1.3 Growth forecast
      • 2.2.1.4 CAGR projections
    • FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 10 CLINICAL MICROBIOLOGY MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 11 DATA TRIANGULATION
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS
  • 2.8 RISK ASSESSMENT
    • TABLE 3 CLINICAL MICROBIOLOGY MARKET: RISK ASSESSMENT
  • 2.9 IMPACT OF ECONOMIC RECESSION ON CLINICAL MICROBIOLOGY MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 12 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 LABORATORY INSTRUMENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 14 MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 CLINICAL MICROBIOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    • FIGURE 16 REGIONAL SNAPSHOT OF CLINICAL MICROBIOLOGY MARKET

4 PREMIUM INSIGHTS

  • 4.1 CLINICAL MICROBIOLOGY MARKET OVERVIEW
    • FIGURE 17 HIGH PREVALENCE OF INFECTIOUS DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
  • 4.2 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT AND COUNTRY (2023)
    • FIGURE 18 GERMANY AND INSTRUMENTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • 4.3 CLINICAL MICROBIOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 CHINA TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
  • 4.4 CLINICAL MICROBIOLOGY MARKET: REGIONAL MIX (2022-2029)
    • FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • 4.5 CLINICAL MICROBIOLOGY MARKET: DEVELOPED VS. EMERGING MARKETS (2024 VS. 2029)
    • FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 CLINICAL MICROBIOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Technological advancements in clinical diagnosis and novel molecular diagnostic-based instruments
      • 5.2.1.2 Rising incidence of infectious diseases and epidemics
      • 5.2.1.3 Increasing R&D programs and public-private investments
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Limited reimbursement policies for clinical microbiology testing procedures
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Improved healthcare infrastructure in emerging countries
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Operational barriers to diagnostic microbiology tests in emerging countries
  • 5.3 PRICING ANALYSIS
    • TABLE 4 AVERAGE SELLING PRICE FOR CLINICAL MICROBIOLOGY TESTING PRODUCTS, 2021-2023
    • FIGURE 23 AVERAGE SELLING PRICE OF CLINICAL MICROBIOLOGY INSTRUMENTS, BY REGION (USD THOUSAND)
    • TABLE 5 AVERAGE SELLING PRICE OF CLINICAL MICROBIOLOGY INSTRUMENTS, BY REGION, 2021-2023
  • 5.4 PATENT ANALYSIS
    • FIGURE 24 PATENT ANALYSIS FOR PCR SYSTEMS (JANUARY 2014-APRIL 2024)
    • 5.4.1 LIST OF MAJOR PATENTS, 2022-2023
    • TABLE 6 LIST OF MAJOR PATENTS IN CLINICAL MICROBIOLOGY MARKET, JANUARY 2022-DECEMBER 2023
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 25 CLINICAL MICROBIOLOGY MARKET: VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 26 CLINICAL MICROBIOLOGY MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 TRADE ANALYSIS
    • 5.7.1 TRADE ANALYSIS FOR MICROSCOPES
    • FIGURE 27 IMPORT DATA FOR MICROSCOPES, BY COUNTRY, 2019-2023 (USD THOUSAND)
    • FIGURE 28 EXPORT DATA FOR MICROSCOPES, BY COUNTRY, 2019-2023 (USD THOUSAND)
    • 5.7.2 TRADE ANALYSIS FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS
    • FIGURE 29 IMPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2019-2023 (USD THOUSAND)
    • FIGURE 30 EXPORT DATA FOR INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2019-2023 (USD THOUSAND)
    • 5.7.3 TRADE ANALYSIS FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS
    • FIGURE 31 IMPORT DATA FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS, BY COUNTRY, 2019-2023 (USD THOUSAND)
    • FIGURE 32 EXPORT DATA FOR MEDICAL, SURGICAL, OR LABORATORY STERILIZERS, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 33 CLINICAL MICROBIOLOGY MARKET: ECOSYSTEM MAP
    • 5.8.1 ROLE IN ECOSYSTEM
    • TABLE 7 CLINICAL MICROBIOLOGY MARKET: ROLE IN ECOSYSTEM
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 34 CLINICAL MICROBIOLOGY MARKET: PORTER'S FIVE FORCES
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 35 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
    • TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
    • 5.10.2 KEY BUYING CRITERIA
    • FIGURE 36 KEY BUYING CRITERIA FOR CLINICAL MICROBIOLOGY PRODUCTS
    • TABLE 10 KEY BUYING CRITERIA FOR CLINICAL MICROBIOLOGY PRODUCTS
  • 5.11 REGULATORY LANDSCAPE
    • 5.11.1 REGULATORY ANALYSIS
      • 5.11.1.1 North America
        • 5.11.1.1.1 US
      • 5.11.1.2 Europe
      • 5.11.1.3 Asia Pacific
      • 5.11.1.4 Rest of the World
    • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.11.2.1 North America: Regulatory bodies, government agencies, and other organizations
      • 5.11.2.2 Europe: Regulatory bodies, government agencies, and other organizations
    • TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.11.2.3 Asia Pacific: Regulatory bodies, government agencies, and other organizations
    • TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
      • 5.11.2.4 Latin America: Regulatory bodies, government agencies, and other organizations
      • 5.11.2.5 Rest of the World: Regulatory bodies, government agencies, and other organizations
  • 5.12 TECHNOLOGY ANALYSIS
    • 5.12.1 KEY TECHNOLOGIES
      • 5.12.1.1 MALDI-TOF mass spectrometry
    • 5.12.2 COMPLEMENTARY TECHNOLOGIES
      • 5.12.2.1 Optical immunosensors
      • 5.12.2.2 Electrochemical immunosensors
    • 5.12.3 ADJACENT TECHNOLOGIES
      • 5.12.3.1 Automated multiplex PCR systems
  • 5.13 KEY CONFERENCES & EVENTS, 2024-2025
    • TABLE 16 CLINICAL MICROBIOLOGY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024-DECEMBER 2025
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 37 REVENUE SHIFT IN CLINICAL MICROBIOLOGY MARKET
  • 5.15 INVESTMENT AND FUNDING SCENARIO
    • 5.15.1 NUMBER OF DEALS
    • FIGURE 38 CLINICAL MICROBIOLOGY MARKET: NUMBER OF DEALS BY KEY PLAYERS, 2018-2022
    • 5.15.2 VALUE OF INVESTOR DEALS
    • FIGURE 39 CLINICAL MICROBIOLOGY MARKET: VALUE OF INVESTOR DEALS, 2018-2022 (USD MILLION)
  • 5.16 UNMET NEEDS

6 CLINICAL MICROBIOLOGY MARKET, BY APPLICATION

  • 6.1 INTRODUCTION
    • TABLE 17 CLINICAL MICROBIOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.2 PHARMACEUTICAL APPLICATIONS
    • 6.2.1 PRESENCE OF WELL-ESTABLISHED PLAYERS AND INCREASED DRUG DEVELOPMENT PIPELINE TO AID MARKET GROWTH
    • TABLE 18 CLINICAL MICROBIOLOGY MARKET FOR PHARMACEUTICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 6.3 CLINICAL APPLICATIONS
    • 6.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND INCREASING FOCUS ON EARLY DIAGNOSIS TO DRIVE MARKET
    • TABLE 19 CLINICAL MICROBIOLOGY MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 6.4 FOOD TESTING APPLICATIONS
    • 6.4.1 HIGH DEMAND FOR PACKAGED FOOD AND EXPANSION OF DAIRY INDUSTRY TO SUPPORT MARKET GROWTH
    • TABLE 20 CLINICAL MICROBIOLOGY MARKET FOR FOOD TESTING APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 6.5 ENERGY APPLICATIONS
    • 6.5.1 INCREASING FOCUS ON ENERGY-EFFICIENT BIOFUEL DEVELOPMENT TO BOOST MARKET GROWTH
    • TABLE 21 CLINICAL MICROBIOLOGY MARKET FOR ENERGY APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 6.6 CHEMICAL & MATERIAL MANUFACTURING APPLICATIONS
    • 6.6.1 INCREASED USE OF MICROBE-DERIVED DYES TO FUEL MARKET GROWTH
    • TABLE 22 CLINICAL MICROBIOLOGY MARKET FOR CHEMICAL & MATERIAL MANUFACTURING APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • 6.7 ENVIRONMENTAL APPLICATIONS
    • 6.7.1 RISING PREVALENCE OF AIR- AND WATER-BORNE DISEASES TO PROPEL MARKET GROWTH
    • TABLE 23 CLINICAL MICROBIOLOGY MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)

7 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA

  • 7.1 INTRODUCTION
    • TABLE 24 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
  • 7.2 RESPIRATORY DISEASES
    • 7.2.1 INCREASING CLINICAL RESEARCH ACTIVITIES FOR ADVANCED DRUG DEVELOPMENT TO DRIVE MARKET
    • TABLE 25 CLINICAL MICROBIOLOGY MARKET FOR RESPIRATORY DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • 7.3 BLOODSTREAM INFECTIONS
    • 7.3.1 GROWING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS TO PROPEL MARKET GROWTH
    • TABLE 26 CLINICAL MICROBIOLOGY MARKET FOR BLOODSTREAM INFECTIONS, BY REGION, 2022-2029 (USD MILLION)
  • 7.4 GASTROINTESTINAL DISEASES
    • 7.4.1 HIGH RISK OF FOOD- AND WATER-BORNE INFECTIONS TO AID MARKET GROWTH
    • TABLE 27 CLINICAL MICROBIOLOGY MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • 7.5 SEXUALLY TRANSMITTED DISEASES
    • 7.5.1 INCREASING EMPHASIS ON EARLY AND EFFECTIVE DISEASE DIAGNOSIS TO BOOST MARKET GROWTH
    • TABLE 28 CLINICAL MICROBIOLOGY MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • 7.6 URINARY TRACT INFECTIONS
    • 7.6.1 RISING NUMBER OF CLINICAL TRIALS FOR DEVELOPMENT OF NEW ANTIBIOTICS TO SUPPORT MARKET GROWTH
    • TABLE 29 CLINICAL MICROBIOLOGY MARKET FOR URINARY TRACT INFECTIONS, BY REGION, 2022-2029 (USD MILLION)
  • 7.7 PERIODONTAL DISEASES
    • 7.7.1 INCREASING R&D INITIATIVES TO STUDY MICROBE-INDUCED DISEASES TO FUEL MARKET GROWTH
    • TABLE 30 CLINICAL MICROBIOLOGY MARKET FOR PERIODONTAL DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • 7.8 OTHER DISEASES
    • TABLE 31 CLINICAL MICROBIOLOGY MARKET FOR OTHER DISEASES, BY REGION, 2022-2029 (USD MILLION)

8 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT

  • 8.1 INTRODUCTION
    • TABLE 32 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • 8.2 INSTRUMENTS
    • TABLE 33 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 34 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 35 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 36 CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY REGION, 2022-2029 (USD MILLION)
    • 8.2.1 LABORATORY INSTRUMENTS
    • TABLE 37 LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 38 LABORATORY INSTRUMENTS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 39 LABORATORY INSTRUMENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 40 LABORATORY INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.1 Incubators
        • 8.2.1.1.1 Rising demand for cell culture applications to drive segment
    • TABLE 41 INCUBATORS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.2 Gram stainers
        • 8.2.1.2.1 Faster and more accurate screening of bacterial pathogens to propel segment growth
    • TABLE 42 GRAM STAINERS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.3 Bacterial colony counters
        • 8.2.1.3.1 Increased focus on accurate bacterial quantification to fuel segment growth
    • TABLE 43 BACTERIAL COLONY COUNTERS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.4 Autoclave sterilizers
        • 8.2.1.4.1 Growing need for infection control in healthcare facilities to support market growth
    • TABLE 44 AUTOCLAVE STERILIZERS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.5 Microbial air samplers
        • 8.2.1.5.1 Need for enhanced air quality monitoring in cleanrooms to accelerate segment growth
    • TABLE 45 MICROBIAL AIR SAMPLERS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.6 Anaerobic culture systems
        • 8.2.1.6.1 Increased research on anaerobic microorganisms to boost segment growth
    • TABLE 46 ANAEROBIC CULTURE SYSTEMS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.7 Petri dish fillers
        • 8.2.1.7.1 Need for minimal bench space and effective control with graphical user interfaces to aid segment growth
    • TABLE 47 PETRI DISH FILLERS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.8 Blood culture systems
        • 8.2.1.8.1 Technological advancements in diagnostic testing to drive segment
    • TABLE 48 BLOOD CULTURE SYSTEMS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.9 Microbial culture systems
        • 8.2.1.9.1 Increase in biopharmaceutical research to augment segment growth
    • TABLE 49 MICROBIAL CULTURE SYSTEMS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.1.10 Other laboratory instruments
    • TABLE 50 OTHER LABORATORY INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 8.2.2 MICROBIOLOGY ANALYZERS
    • TABLE 51 LIST OF COMMERCIALLY AVAILABLE MICROBIOLOGY ANALYZERS, 2023-2024
    • TABLE 52 MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 53 MICROBIOLOGY ANALYZERS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 54 MICROBIOLOGY ANALYZERS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 55 MICROBIOLOGY ANALYZERS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.2.1 Molecular diagnostic instruments
        • 8.2.2.1.1 Advancements in multiplexing techniques and high adoption of genomics-based analysis to aid market growth
    • TABLE 56 MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.2.2 Microscopes
        • 8.2.2.2.1 Rising demand for high-resolution imaging to propel market growth
    • TABLE 57 MICROSCOPES MARKET, BY REGION, 2022-2029 (USD MILLION)
      • 8.2.2.3 Mass spectrometers
        • 8.2.2.3.1 Increased applications in proteomics and metabolomics to boost market growth
    • TABLE 58 MASS SPECTROMETERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 8.3 REAGENTS
    • TABLE 59 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 60 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 61 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 62 CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY REGION, 2022-2029 (USD MILLION)
    • 8.3.1 PATHOGEN-SPECIFIC KITS
      • 8.3.1.1 Growing private-public initiatives for research to support market growth
    • TABLE 63 PATHOGEN-SPECIFIC KITS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 64 PATHOGEN-SPECIFIC KITS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 65 PATHOGEN-SPECIFIC KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
    • 8.3.2 GENERAL REAGENTS
      • 8.3.2.1 Rising demand for diagnostic tests for pathogen detection to propel segment growth
    • TABLE 66 GENERAL REAGENTS MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 67 GENERAL REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 68 GENERAL REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 8.4 MEDIA & SERA
    • 8.4.1 RISING DEMAND FOR STANDARDIZED CULTURE MEDIA FOR MICROBIOLOGICAL TESTING TO DRIVE MARKET
    • TABLE 69 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 70 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 71 CLINICAL MICROBIOLOGY MARKET FOR MEDIA & SERA, BY REGION, 2022-2029 (USD MILLION)

9 CLINICAL MICROBIOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 72 NUMBER OF CLINICAL LABORATORIES, BY TIER, 2023
    • TABLE 73 CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 9.2 HOSPITALS & DIAGNOSTIC CENTERS
    • 9.2.1 GROWING INCIDENCE OF TARGET DISEASES TO DRIVE MARKET
    • TABLE 74 CLINICAL MICROBIOLOGY MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2022-2029 (USD MILLION)
  • 9.3 CONTRACT TESTING LABORATORIES
    • 9.3.1 CONTINUOUS OUTSOURCING OF DRUG TESTING PROCEDURES TO LABORATORY SERVICE PROVIDERS TO AID MARKET GROWTH
    • TABLE 75 CLINICAL MICROBIOLOGY MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 INCREASED USE OF ADVANCED MOLECULAR DIAGNOSTIC PRODUCTS FOR DISEASE DIAGNOSIS TO AUGMENT MARKET GROWTH
    • TABLE 76 CLINICAL MICROBIOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)

10 CLINICAL MICROBIOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 77 SALES VOLUME IN US, UK, AND CHINA, BY PRODUCT TYPE (2023)
    • TABLE 78 CLINICAL MICROBIOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 40 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET SNAPSHOT
    • TABLE 79 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 80 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 81 NORTH AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 82 NORTH AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 83 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 84 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 85 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022-2029(USD MILLION)
    • TABLE 86 NORTH AMERICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 US to dominate clinical microbiology market during study period
    • TABLE 87 US: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 88 US: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 89 US: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 90 US: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 91 US: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Supportive government initiatives and increased research funding to boost market growth
    • TABLE 92 CANADA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 93 CANADA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 94 CANADA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 95 CANADA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 96 CANADA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 97 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 98 EUROPE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 99 EUROPE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 100 EUROPE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 101 EUROPE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 102 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 103 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 104 EUROPE: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • 10.3.1 EUROPE: RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Growing outsourcing of diagnostic testing by hospitals to fuel market growth
    • TABLE 105 GERMANY: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 106 GERMANY: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 107 GERMANY: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 108 GERMANY: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 109 GERMANY: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Rising acceptance of genome-based diagnostic techniques to fuel market growth
    • TABLE 110 UK: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 111 UK: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 112 UK: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 113 UK: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 114 UK: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Favorable healthcare reforms and investments in diagnostic infrastructure to propel market growth
    • TABLE 115 FRANCE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 116 FRANCE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 117 FRANCE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 118 FRANCE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 119 FRANCE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Improved healthcare services and better disease surveillance to fuel market growth
    • TABLE 120 ITALY: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 121 ITALY: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 122 ITALY: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 123 ITALY: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 124 ITALY: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Well-established research centers and stringent food regulations to augment market growth
    • TABLE 125 SPAIN: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 126 SPAIN: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 127 SPAIN: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 128 SPAIN: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 129 SPAIN: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 130 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029(USD MILLION)
    • TABLE 131 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 132 REST OF EUROPE: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 133 REST OF EUROPE: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 134 REST OF EUROPE: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 41 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET SNAPSHOT
    • TABLE 135 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029(USD MILLION)
    • TABLE 136 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 138 ASIA PACIFIC: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 139 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 141 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 10.4.2 JAPAN
      • 10.4.2.1 Technological advancements in healthcare and high geriatric population to aid market growth
    • TABLE 143 JAPAN: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 144 JAPAN: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 145 JAPAN: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 146 JAPAN: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 147 JAPAN: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Increasing government focus on disease prevention to drive market
    • TABLE 148 CHINA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 149 CHINA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 150 CHINA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 151 CHINA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 152 CHINA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Rapidly increasing population and high incidence of infectious diseases to propel market growth
    • TABLE 153 INDIA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 154 INDIA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 155 INDIA LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 156 INDIA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 157 INDIA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Rising public-private investments and growing research on diagnostic applications to drive market
    • TABLE 158 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 159 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 160 AUSTRALIA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 161 AUSTRALIA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 162 AUSTRALIA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Strong government support and increased adoption of advanced diagnostic technologies to aid market growth
    • TABLE 163 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 164 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 165 SOUTH KOREA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 166 SOUTH KOREA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 167 SOUTH KOREA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.7 REST OF ASIA PACIFIC
    • TABLE 168 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 169 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 170 REST OF ASIA PACIFIC: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 171 REST OF ASIA PACIFIC: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 172 REST OF ASIA PACIFIC: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 173 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 174 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 175 LATIN AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 176 LATIN AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 177 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 178 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 179 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 180 LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • 10.5.1 LATIN AMERICA: RECESSION IMPACT
    • 10.5.2 BRAZIL
      • 10.5.2.1 High healthcare expenditure and presence of key manufacturers to support market growth
    • TABLE 181 BRAZIL: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 182 BRAZIL: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 183 BRAZIL: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 184 BRAZIL: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 185 BRAZIL: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.5.3 MEXICO
      • 10.5.3.1 Supportive government initiatives and increased healthcare investments to augment market growth
    • TABLE 186 MEXICO: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 187 MEXICO: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 188 MEXICO: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 189 MEXICO: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 190 MEXICO: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.5.4 REST OF LATIN AMERICA
    • TABLE 191 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 192 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 193 REST OF LATIN AMERICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 194 REST OF LATIN AMERICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 195 REST OF LATIN AMERICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • TABLE 196 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 197 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 198 MIDDLE EAST & AFRICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 199 MIDDLE EAST & AFRICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 200 MIDDLE EAST AND AFRICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 201 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2022-2029 (USD MILLION)
    • TABLE 202 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
    • TABLE 203 MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY COUNTRY, 2022-2029(USD MILLION)
    • 10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • 10.6.2 GCC COUNTRIES
      • 10.6.2.1 High incidence of infectious diseases and technological advancements to fuel market growth
    • TABLE 204 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
    • TABLE 205 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 206 GCC COUNTRIES: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 207 GCC COUNTRIES: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 208 GCC COUNTRIES: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)
    • 10.6.3 REST OF MIDDLE EAST & AFRICA
    • TABLE 209 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2022-2029(USD MILLION)
    • TABLE 210 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR INSTRUMENTS, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 211 REST OF MIDDLE EAST & AFRICA: LABORATORY INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 212 REST OF MIDDLE EAST & AFRICA: MICROBIOLOGY ANALYZERS MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 213 REST OF MIDDLE EAST & AFRICA: CLINICAL MICROBIOLOGY MARKET FOR REAGENTS, BY TYPE, 2022-2029 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET
    • FIGURE 42 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE ANALYSIS
    • FIGURE 43 REVENUE ANALYSIS FOR KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET (2021-2023)
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET (2023)
    • TABLE 214 CLINICAL MICROBIOLOGY MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 PERVASIVE PLAYERS
    • 11.5.3 EMERGING LEADERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 45 CLINICAL MICROBIOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
    • FIGURE 46 CLINICAL MICROBIOLOGY MARKET: COMPANY FOOTPRINT
      • 11.5.5.2 Product footprint
    • TABLE 215 CLINICAL MICROBIOLOGY MARKET: PRODUCT FOOTPRINT
      • 11.5.5.3 Application footprint
    • TABLE 216 CLINICAL MICROBIOLOGY MARKET: APPLICATION FOOTPRINT
      • 11.5.5.4 End user footprint
    • TABLE 217 CLINICAL MICROBIOLOGY MARKET: END USER FOOTPRINT
      • 11.5.5.5 Region footprint
    • TABLE 218 CLINICAL MICROBIOLOGY MARKET: REGION FOOTPRINT
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 DYNAMIC COMPANIES
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 STARTING BLOCKS
    • FIGURE 47 CLINICAL MICROBIOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • TABLE 219 CLINICAL MICROBIOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES
    • TABLE 220 CLINICAL MICROBIOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 11.7 VALUATION & FINANCIAL METRICS
    • FIGURE 48 EV/EBITDA OF KEY VENDORS
    • FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
  • 11.8 BRAND/PRODUCT COMPARISON
    • FIGURE 50 CLINICAL MICROBIOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES
    • TABLE 221 CLINICAL MICROBIOLOGY MARKET: PRODUCTS LAUNCHES, JANUARY 2021-MAY 2024
    • 11.9.2 DEALS
    • TABLE 222 CLINICAL MICROBIOLOGY MARKET: DEALS, JANUARY 2021-MAY 2024
    • 11.9.3 OTHER DEVELOPMENTS
    • TABLE 223 CLINICAL MICROBIOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 BIOMERIEUX
    • TABLE 224 BIOMERIEUX: COMPANY OVERVIEW
    • FIGURE 51 BIOMERIEUX: COMPANY SNAPSHOT (2023)
    • TABLE 225 BIOMERIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 226 BIOMERIEUX: DEALS, JANUARY 2021-MAY 2024
    • 12.1.2 DANAHER CORPORATION
    • TABLE 227 DANAHER CORPORATION: COMPANY OVERVIEW
    • FIGURE 52 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 228 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 229 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.3 BECTON, DICKINSON AND COMPANY
    • FIGURE 53 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
    • TABLE 231 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 232 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 233 BECKTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021-MAY 2024
    • TABLE 234 BECKTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.4 ABBOTT
    • FIGURE 54 ABBOTT: COMPANY SNAPSHOT (2023)
    • TABLE 236 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 237 ABBOTT: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.5 F. HOFFMANN-LA ROCHE LTD.
    • FIGURE 55 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 239 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 240 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 241 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-MAY 2024
    • TABLE 242 F. HOFFMAN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.6 THERMO FISHER SCIENTIFIC INC.
    • TABLE 243 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 56 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 244 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 245 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 246 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-MAY 2024
    • 12.1.7 AGILENT TECHNOLOGIES, INC.
    • FIGURE 57 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 248 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 249 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-MAY 2024
    • 12.1.8 BRUKER
    • TABLE 250 BRUKER: COMPANY OVERVIEW
    • FIGURE 58 BRUKER: COMPANY SNAPSHOT (2022)
    • TABLE 251 BRUKER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 252 BRUKER: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 253 BRUKER: DEALS, JANUARY 2021-MAY 2024
    • 12.1.9 HOLOGIC, INC.
    • TABLE 254 HOLOGIC, INC.: COMPANY OVERVIEW
    • FIGURE 59 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 255 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 256 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 257 HOLOGIC, INC.: DEALS, JANUARY 2021-MAY 2024
    • 12.1.10 MERCK KGAA
    • TABLE 258 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • TABLE 259 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 260 MERCK KGAA: DEALS, JANUARY 2021-MAY 2024
    • TABLE 261 MERCK KGAA: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.11 BIO-RAD LABORATORIES, INC.
    • TABLE 262 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
    • FIGURE 61 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 263 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 264 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-MAY 2024
    • TABLE 265 BIO-RAD LABORATORIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.12 QIAGEN
    • TABLE 266 QIAGEN: COMPANY OVERVIEW
    • FIGURE 62 QIAGEN: COMPANY SNAPSHOT (2023)
    • TABLE 267 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 268 QIAGEN: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
    • TABLE 269 QIAGEN: DEALS, JANUARY 2021-MAY 2024
    • 12.1.13 SHIMADZU CORPORATION
    • TABLE 270 SHIMADZU CORPORATION: COMPANY OVERVIEW
    • FIGURE 63 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 271 SHIMADZU CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 12.1.14 NEOGEN CORPORATION
    • TABLE 272 NEOGEN CORPORATION: COMPANY OVERVIEW
    • FIGURE 64 NEOGEN CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 273 NEOGEN CORPORATION: PRODUCTS/ SERVICES/SOLUTIONS OFFERED
    • TABLE 274 NEOGEN CORPORATION: DEALS, JANUARY 2021-MAY 2024
    • 12.1.15 SIEMENS HEALTHINEERS AG
    • TABLE 275 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
    • FIGURE 65 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
    • TABLE 276 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 12.1.16 HARDY DIAGNOSTICS
    • TABLE 277 HARDY DIAGNOSTICS: COMPANY OVERVIEW
    • TABLE 278 HARDY DIAGNOSTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 12.1.17 EMSL ANALYTICAL, INC.
    • TABLE 279 EMSL ANALYTICAL, INC.: COMPANY OVERVIEW
    • TABLE 280 EMSL ANALYTICAL, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 12.1.18 LIOFILCHEM SRL
    • TABLE 281 LIOFILCHEM SRL: COMPANY OVERVIEW
    • TABLE 282 LIOFILCHEM SRL: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 12.1.19 TCS BIOSCIENCES
    • TABLE 283 TCS BIOSCIENCES: COMPANY OVERVIEW
    • TABLE 284 TCS BIOSCIENCES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 12.1.20 COLE-PARMER INSTRUMENT COMPANY, LLC
    • TABLE 285 COLE-PARMER INSTRUMENT COMPANY, LLC: COMPANY OVERVIEW
    • TABLE 286 COLE-PARMER INSTRUMENT COMPANY, LLC: PRODUCTS/SERVICES/ SOLUTIONS OFFERED
  • 12.2 OTHER PLAYERS
    • 12.2.1 MEMMERT GMBH + CO.KG
    • TABLE 287 MEMMERT GMBH + CO.KG COMPANY OVERVIEW
    • 12.2.2 VACUTEST KIMA S.R.L
    • TABLE 288 VACUTEST KIMA S.R.L.: COMPANY OVERVIEW
    • 12.2.3 RAPID MICRO BIOSYSTEMS, INC.
    • TABLE 289 RAPID MICRO BIOSYSTEMS, INC..: COMPANY OVERVIEW
    • 12.2.4 BIOTECHNOLOGY SOLUTIONS TX, LLC
    • TABLE 290 RAPID MICRO BIOSYSTEMS, INC.: COMPANY OVERVIEW
    • 12.2.5 ARROW DIAGNOSTICS
    • TABLE 291 ARROW DIAGNOSTICS: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS